[144] Ligand Pharmaceuticals Inc. SEC Filing

Rhea-AI Filing Summary

Ligand Pharmaceuticals Inc. (LGND) filed a Form 144 indicating a planned disposition of common shares. The notice covers the proposed sale of 934 shares through UBS Financial Services, Inc. at an aggregate market value of $116,750, representing approximately 0.0048 % of the company’s 19,294,168 shares outstanding. The anticipated sale date is 07 / 10 / 2025. The seller originally acquired the shares in separate transactions on 06 / 06 / 2019 and 06 / 04 / 2021 directly from the issuer. No other sales were reported for the past three months, and no material adverse information is acknowledged by the filer as required under Rule 144.

Insights

Securities Analyst

TL;DR: Routine Form 144 for 934 LGND shares (~$117k); negligible 0.005 % of float—no material impact on valuation or liquidity.

The filing signals an insider’s intent to sell 934 LGND common shares via UBS on or about 10 July 2025. At roughly one-twentieth of one percent of outstanding stock, the trade is immaterial to daily volume and unlikely to influence price discovery. No pattern of sustained selling is evident, as the filer reported no other dispositions within the last three months. Because Form 144 precedes, rather than confirms, an actual transaction, investors should view it as a routine compliance step rather than a firm indication of bearish sentiment. Overall impact is neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	934	116750.00	19294168	07/10/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/06/2019	Various	Issuer			467	06/06/2019	NA
Common	06/04/2021	Various	Issuer			467	06/04/2021	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Ligand Pharmaceuticals (LGND) shares are covered by this Form 144?

The notice covers 934 common shares of LGND.

What is the aggregate market value of the shares noted in the filing?

The 934 shares have an aggregate market value of $116,750.

When is the approximate sale date for the LGND shares?

The filer lists an approximate sale date of 07/10/2025.

What percentage of Ligand’s outstanding shares does this sale represent?

The proposed sale equals about 0.0048 % of the 19,294,168 shares outstanding.

Which broker is handling the proposed LGND share sale?

The shares are to be sold through UBS Financial Services, Inc. in New York.